{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:23:59Z","timestamp":1788571439139,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>Currently, there is no optimal dose recommendation for a 120-h continuous infusion of 5-fluorouracil <jats:italic>via<\/jats:italic> arterial cannulation for advanced T-stage nasopharyngeal carcinoma (NPC). Thus, the aim of this study was to determine the maximum tolerated dose (MDT), along with the efficacy, late adverse events, and 10-year survival outcome of 5-fluorouracil administered continuously for 120\u00a0h combined with cisplatin <jats:italic>via<\/jats:italic> the superficial temporal artery in patients with advanced T-stage NPC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Fifty-one patients with histologically confirmed advanced T-stage NPC were eligible for inclusion in this clinical trial. The patients received induction chemotherapy consisting of cisplatin (20 mg\/m<jats:sup>2<\/jats:sup>\/d for 1\u20135 d) and 5-fluorouracil, administered continuously for 120\u00a0h at different dose gradients <jats:italic>via<\/jats:italic> a superficial temporal artery. To identify the MTD of 5-fluorouracil infused arterially, we employed a 3 + 3 design during study phase I. The initial dose administered was 200 mg\/m<jats:sup>2<\/jats:sup>\/d, which then was gradually escalated by 50 mg\/m<jats:sup>2<\/jats:sup>\/d until the MTD was reached. Following two cycles of induction chemotherapy, current radical chemoradiotherapy commenced. We assessed the efficacy, survival, toxicity, and quality of life of patients following treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response (complete response + partial response) rates following induction chemotherapy in the primary mass and lymph nodes were 100% and 100%, respectively. All 51 (100%) patients achieved T-category down-staging after intra-arterial chemotherapy. The MTD was 450 mg\/m<jats:sup>2<\/jats:sup>\/d for 120\u00a0h. No late neurological toxicities, such as brain stem injury, temporal lobe necrosis, and spinal cord injury, were observed. The 5- and 10-year overall survival (OS) rates were 78.0% and 71.7%, respectively, with a median OS of 131 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Continuous infusion of 5-fluorouracil combined with cisplatin <jats:italic>via<\/jats:italic> the superficial temporal artery showed promising survival benefits and few toxicities in patients with advanced T-stage NPC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.868070","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T08:51:01Z","timestamp":1658911861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["5-Fluorouracil combined with cisplatin via arterial induction for advanced T-stage nasopharyngeal carcinoma: A 10-year outcome of a phase I\/II study"],"prefix":"10.3389","volume":"12","author":[{"given":"Li","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiRong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianWen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QingLian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiJia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChangLing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingBo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.01.002","article-title":"Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A treatment paradigm also applicable to patients in southeast Asia","volume":"35","author":"Lu","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.07.062","article-title":"Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging","volume":"73","author":"Mao","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.oraloncology.2017.12.004","article-title":"Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)","volume":"77","author":"Au","year":"2018","journal-title":"Oral Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.02.003","article-title":"Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma","volume":"87","author":"Lee","year":"2008","journal-title":"Radiother Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1400-3","article-title":"Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: A microdialysis study","volume":"67","author":"Konings","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001115)89:10<2099::AID-CNCR10>3.0.CO;2-4","article-title":"A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. phase I study","volume":"89","author":"Fuwa","year":"2000","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.01.011","article-title":"Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer","volume":"79","author":"Mitsudo","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","first-page":"998","article-title":"Controversial issues in 5-fluorouracil infusion use. dose intensity, treatment duration, and cost comparisons","volume":"70","author":"Anderson","year":"1992","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830415)51:8<1353::AID-CNCR2820510805>3.0.CO;2-I","article-title":"Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck","volume":"51","author":"Decker","year":"1983","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? an individual patient data network meta-analysis","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.06.012","article-title":"Clinical and dosimetric characteristics of temporal lobe injury following intensity modulated radiotherapy of nasopharyngeal carcinoma","volume":"104","author":"Su","year":"2012","journal-title":"Radiother Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16664","DOI":"10.1038\/srep16664","article-title":"Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy","volume":"5","author":"Du","year":"2015","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.03.001","article-title":"A phase I\/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma","volume":"63","author":"Johnson","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-8375(98)00018-9","article-title":"New superselective intra-arterial infusion via superficial temporal artery for cancer of the tongue and tumour tissue platinum concentration after carboplatin (CBDCA) infusion","volume":"34","author":"Tohnai","year":"1998","journal-title":"Oral Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.03.005","article-title":"Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: Analysis of therapeutic results in 112 cases","volume":"111","author":"Mitsudo","year":"2014","journal-title":"Radiother Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hed.10000","article-title":"Swallowing and speech ability after treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation","volume":"24","author":"Newman","year":"2002","journal-title":"Head Neck"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<1912::AID-CNCR6>3.0.CO;2-S","article-title":"Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma","volume":"86","author":"Heng","year":"1999","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90307-7","article-title":"A new staging system for nasopharyngeal carcinoma in China","volume":"30","author":"Min","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22396","article-title":"Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: Comparisons of four radiotherapy techniques","volume":"109","author":"Fang","year":"2007","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2011.14.4.289","article-title":"Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer","volume":"14","author":"Lee","year":"2011","journal-title":"J Breast Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.radonc.2017.07.020","article-title":"Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial","volume":"126","author":"Yang","year":"2018","journal-title":"Radiother Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.868070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T08:51:03Z","timestamp":1658911863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.868070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":26,"alternative-id":["10.3389\/fonc.2022.868070"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.868070","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"article-number":"868070"}}